Representative Marjorie Taylor Greene recently disclosed a modest investment in Merck & Co., alongside a flurry of similar-sized purchases in tech, energy, and fitness apparel stocks. On April 9th, ...

Big-money investors, aka “whales,” have taken a cautiously bearish turn on Airbnb’s options, making more put trades than ...

Bessemer Group Inc. just spilled most of its Starbucks stock—selling a piping hot 91.1% of its stake in the fourth quarter.

Legacy Financial Advisors trimmed its Lockheed Martin stake by nearly 38% last quarter, offloading 1,048 shares and leaving ...

UBS Group slashed Bristol-Myers Squibb’s price target from $60 to $54, keeping its rating at a neutral "meh." Other analysts ...

Waterloo Capital L.P. joined the investor parade by grabbing 4,501 PayPal shares, throwing $384,000 into the fintech arena.

Oppenheimer trimmed KLA’s price target from $850 to $700, joining a chorus of analysts adjusting expectations in the ...

Analysts are playing financial ping-pong with The Cigna Group’s price target, but the net effect is positive. Truist ...

Analysts can't seem to agree on Marsh & McLennan's stock direction, but one thing's clear—it’s making headlines. Keefe, ...

Christopher D’Ambrosio, a corporate VP at ADP, sold 478 shares for $140,120 while the stock hovered near a 52-week high. This ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

Wellington Management Group shaved off a tiny sliver of its CVS Health stake, reducing it by 1.8% during Q4. The firm still ...